Ricin toxin (RT) ranks at the top of the list of potential bioweapons of concern to civilian 32 and military personnel alike due to its high potential for morbidity and mortality after 33 inhalation. In non-human primates, aerosolized ricin triggers a severe acute respiratory 34 distress characterized by perivascular and alveolar edema, neutrophilic infiltration, and 35 severe necrotizing bronchiolitis and alveolitis. There are currently no approved 36 countermeasures for ricin intoxication. In this report, we demonstrate the therapeutic 37 potential of huPB10, a toxin-neutralizing humanized monoclonal antibody (MAb) against 38 an immunodominant epitope on ricin's enzymatic A chain (RTA). Five rhesus macaques 39 that received intravenous huPB10 (10 mg/kg) four hours after lethal dose ricin aerosol 40 exposure all survived the toxin challenge, as compared to control animals, which 41 succumbed to ricin intoxication within 30 h. Antibody treatment at 12 h after ricin 42 exposure resulted in the survival of only one of five monkeys, indicating that, in the 43 majority of animals, ricin intoxication and local tissue damage had progressed beyond 44 the point where huPB10 intervention was beneficial. Change in pro-inflammatory 45 cytokine/chemokines levels in bronchial alveolar lavage fluids before and after toxin 46 challenge successfully clustered monkeys based on survival, as well as treatment 47 RT inhalation (3, 16). PB10 was first described as a murine MAb with potent-toxin 77 neutralizing activity in vitro and in vivo (17). PB10 recognizes an immunodominant 78 epitope situated at the apex of RTA, relative to RTB (18, 19). Chimeric (cPB10) and fully 79 humanized (huPB10) versions of PB10 retain in vitro toxin-neutralizing activity and have 80 been shown to passively protect mice against lethal dose of RT administered by 81 injection or inhalation (20, 21). It was also demonstrated that huPB10 can rescue mice 82 from intoxication if administered 4-6 h after exposure (21). Based on these preliminary 83 findings, assessed the therapeutic potential of huPB10 in a well-established nonhuman 84 Wong J, Korcheva V, Jacoby DB, and Magun BE. Proinflammatory responses of 354 human airway cells to ricin involve stress-activated protein kinases and NF-kappaB.
group. IL-6 was the most apparent marker of ricin intoxication. This study represents 48 the first demonstration in nonhuman primates that the lethal effects of inhalational ricin 49 exposure can be negated by a drug candidate and opens up a path forward for product 50 development. 51
.
54
Introduction 55 Ricin toxin (RT) is considered a high priority biothreat agent by the Centers for 56
Disease Control and Prevention (CDC), the US Department of Defense (DOD), and 57 NATO due to it's accessibility, stability, and high toxicity especially by the aerosol route. 58
(1, 2). In nonhuman primates (NHPs), inhalation of RT elicits the clinical equivalent of 59 acute respiratory distress syndrome (ARDS), characterized by widespread apoptosis of 60 alveolar macrophages, intra-alveolar edema, neutrophilic infiltration, accumulation of 61 pro-inflammatory cytokines, and fibrinous exudate (3, 4) . Ricin also damages the lung 62 mucosa and triggers vascular leak due to direct damage to endothelial cells (5). Similar 63 effects are observed in mice, rats and swine (6-10). RT is derived from castor beans 64 (Ricinus communis) and is a 65 kDa heterodimeric glycoprotein consisting of two 65 subunits, RTA and RTB, joined via a single disulfide bond. RTB binds to glycoproteins 66 and glycolipids on mammalian cells and facilitates the retrograde transport of RT to the 67 endoplasmic reticulum (ER). In the ER, RTA is liberated from RTB and retrotranslocated 68 into the cytoplasm via the Sec61 complex (11). RTA is an RNA N-glycosidase that 69 catalyzes the hydrolysis of a conserved adenine residue within the sarcin/ricin loop of 70 28S rRNA, resulting in the inhibition of protein synthesis (12, 13) and the activation of 71 apoptosis (14) . Alveolar macrophages are particularly sensitive to the cytotoxic effects 72 and secrete an array of pro-inflammatory cytokines before undergoing apoptosis (8, 9, 73 15) . 74
In this report we investigated the potential of a humanized monoclonal antibody 75 (MAb) huPB10 to serve as a therapeutic in an established Rhesus macaques model of 76 primate (NHP) model of ricin aerosol challenge (16) . The NHP is believed to be the 85 model most representative of aerosolized exposure. 86 87
Results

88
A total of 12 rhesus macaques (~7 kg; range 3.8-10.2 kg) bred at Tulane National 89
Primate Research Center (TNPRC) were randomly assigned to three experimental 90 groups and then challenged with RT by small particle aerosol at a target dose of 18 91 µg/kg (Table 1; Figure 1) . Animal studies were conducted in strict compliance with 92 protocols approved by TNPRC's Institutional Animal Care and Use Committee (IACUC). 93
Group 1 (n=2) received intravenous administration of saline 4 h post challenge. Animals 94 in groups 2 and 3 received huPB10 at 4 h or 12 h post challenge, respectively ( Table  95 1). huPB10 was administered intravenously at a final dose of 10 mg/kg ( Table S1 ). The 96 macaques were subjected to whole body plethysmography and radiotelemetry over the 97 course of the study. Animals surviving on day 14 post challenge were euthanized and 98 subjected to complete necropsy and histopathological analysis. Serum and bronchial 99 alveolar lavage (BAL) fluids were collected from the animals before and 24 h after 100 exposure to RT. 101
Control animals (n=2) succumbed to RT toxicosis within 36 hours of exposure. Finally, only one of the five animals in Group 3 that received huPB10 at 12 h 117 survived RT challenge (Table 1; Figure 1 ; P<0.01 and P<0.05 compared to controls 118 and +4 h group, respectively). The remaining four animals succumbed to RT intoxication 119 between 44 and 72 h post challenge and followed a clinical course similar to the control 120 animals. HuPB10 was detected in the sera and BAL fluids collected at 24 h post RT 121 challenge, indicating that biodistribution of huPB10 was similar between groups 2 and 3. 122
Gross examination of the lungs from sham-treated control animals showed 123 coalescing hemorrhage with frothy exudate marked by fibrin in lung parenchyma 124 (Figure S1). The lungs of control animals were grossly described as fibrinosuppurative 125 bronchointerstitial pneumonia with pulmonary edema and bronchial epithelial necrosis, 126 with severe fibrinosuppurative lymphadenitis in the bronchial lymph nodes. The wet 127 weights of control animal lungs were >150 grams in contrast to a normal wet lung 128 weight of ~30-40 grams in naïve animals of approximately the same body weight. 129
Histologically, the lungs of sham-treated animals showed hallmark inflammation 130 consistent with RT-induced injury, characterized by marked edema, corresponding 131 hemorrhage, and numerous infiltrates. The pathological outcome of the four animals in 132 Animals in Group 3 that succumbed to RT intoxication resembled the control animals. 133
There was extensive pulmonary congestion, edema, inflammation with infiltrates, and 134 punctate hemorrhage evident. Gross lung weights were similar to RT-challenged control 135 animals (>140 g) with clear signs of hemorrhage. 136
Pathological analysis of the lung tissues collected at the time of euthanasia (day 21 137 post challenge) from the five survivors in Group 2 that had been treated with huPB10 at 138 4 h and the single animal in Group 3 (DR61) revealed evidence of chronic inflammation 139 and a distinctive fibrosis proximal to the respiratory bronicholes, reminiscent of past 140 studies in which animals had received sub-lethal exposures to RT (22) . 141
Sera and BAL fluids collected before (day -7) and 24 h post RT challenge were 142 subjected to analysis with a 29-plex cytokine/chemokine/growth factor Luminex array as 143 a means to assess the impact of huPB10 on local and systemic inflammatory that were significantly different in serum post-versus pre-challenge; 11 cytokines were 146 increased, while one (IL-8) was decreased ( Figure 3A; S2) . Most notable were IL-6 147 (~500-fold increase) and IL-1RA (~256-fold increase). VEGF was also elevated, 148 possibly reflecting response to pulmonary insult. Analysis of sera from animals that 149 received huPB10 at 4 h post challenge indicated that only four cytokine/chemokines 150 were significantly different from pre-challenge levels (3 up;1 down), including a ~4-fold 151 increase in IL-6. IL-1RA and VEGF levels were unchanged. In animals that received 152 huPB10 at 12 h after RT challenge, a total of six cytokines/chemokines changed relative 153 to pre-challenge levels, although the magnitude of these changes was lower than that if The impact of huPB10 intervention was much more apparent in BAL fluids than in 160 sera ( Figure 3B) . Within group 2, a total of 21 cytokines/chemokines were significantly 161 elevated following RT challenge (as compared to pre-challenge levels), with IL-6 being 162 the most pronounced. In group 3, there were 25 cytokines/chemokines that were 163 significantly elevated compared to pre-challenge levels. Seven cytokines/chemokines 164 differed between the groups 2 and 3 with the most notable being IL-6, which was 32-fold 165 elevated in group 2 and 181-fold elevated in group 3. PCA successfully clustered 166 animals by both group and survival status, demonstrating that the localized cytokine 167 responses in the BAL are more closely related to survival than the systemic responses 168 (Figure S3D-E) . The relative contributions of the different cytokines/chemokines 169 responsible for segregating the animals into clusters are shown in Figure S3F . The results of this study constitute a significant advance in longstanding efforts to 173 develop effective medical countermeasures against RT inhalation (2, 23). Foremost, it is 174 the first demonstration in NHPs that a MAb can rescue animals from the lethal effects of products for humans must adhere to the Food and Drug Administration's (FDA) Animal 177
Rule; human challenge studies with RT are obviously unethical. The well-established 178 model of aerosolized RT challenge in Rhesus macaques was a prerequisite for the 179 therapeutic study conducted herein (3, 16, 24) . Comparative models in mice (6, 8, 25) 180 and swine (10) may also be important for therapeutic development under Animal Rule 181 guidelines. The fact that all five animals in group 2 (+4 h huPB10 intervention), and one 182 animal in group 3 (+12 h huPB10 intervention), survived exposure to RT indicates that a 183 significant proportion of RT remains accessible to huPB0 in the alveolar space and/or 184 interstitial fluids for hours after inhalational exposure. This finding is consistent with 185 reports in mice with huPB10 and other anti-RT MAbs (6, 7, 21, 26) , but surprising all 186 the same considering the extraordinary sensitivity of the lung mucosa to the effects of 187 toxin exposure (27). 188
We postulate that high dose intravenous delivery of huPB10 results in the 189 accumulation of huPB10 within the lung mucosa and alveolar space where it can 190 engage free (soluble) or receptor-bound RT. Indeed, IV administration of recombinant 191
anti-viral IgG1 MAbs results a corresponding linear distribution of antibodies lung (28, 192 29) . Whether transudation or active transport of serum antibodies into the lung mucosa 193 is triggered by RT exposure has not been evaluated. Nonetheless, once in the lung 194 mucosa, huPB10 presumably limits toxin uptake into target cells (e.g., macrophages 195 and airway epithelial cells) and/or interferes with ricin intracellular transport in the event 196 that endocytosis of RT-antibody complexes should occur (30, 31) . Work by Magun and 197 colleagues made it clear more than a decade ago that protecting alveolar macrophages 198 is paramount in limiting toxin-induced lung damage (9, 32). 199
It is worth underscoring the value of the 29-plex monkey cytokine/chemokine/growth 200 factor array in not only identifying local inflammatory markers like IL-6 that arise 201 following RT exposure but also enabling through PCA the unbiased clustering of 202 specific animals based on survival or experimental group. Identifying an inflammatory 203 "fingerprint" associated with RT exposure has obvious applications in diagnostics, 204 especially in the context of biodefense where early clinical symptoms following 205 exposure to different toxins and pathogens may in fact be indistinguishable (33). As consistent with what has been observed in mice (34). IL-6 is a particularly potent driver 208 of pulmonary inflammation and could very well be a major contributor to RT-induced 209 pathology in conjunction with RT's other properties, including agglutinin activity and the 210 capacity to induce vascular leak syndrome (5, 35) . We recently reported that human 211 lung epithelial cell lines preferentially secrete IL-6 following RT exposure, especially in 212 the presence of pro-apoptotic factors like TRAIL (36). It has been suggested that anti-213 inflammatory agents may extend the therapeutic window of anti-RT MAbs by 214 suppressing bystander tissue damage (26). Whether such directed immunotherapies 215 would have utility in the context of potent toxin-neutralizing antibody like huPb10 216 remains to be seen. At least early intervention with huPB10 was sufficient to render RT 217 effectively inert within the context of the lung and it seems unlikely that supplementing 218 treatment with anti-inflammatory agents would afford much additional benefit. 219 220
Methods 221
Ricin toxin and huPB10. Purified ricin toxin derived from castor beans (Ricinus 222 communis) was produced as previously described (37) . HuPB10 was expressed using a 223
Nicotiana benthamiana-based manufacturing platform. The properties of huPB10 used 224 in this study are shown in Table S1 . Accreditation of Laboratory Animal Care (AAALAC). Aerosolization, dosing and delivery 230 of RT were performed as described (16). The LD50 of ricin is 5.8 µg/kg body weight and 231 the target dose for this experiment was set at the equivalent of three LD50s (»18 µg/kg). 232
The mean inhaled dose of ricin across all animals was 4.4 ± 1.4 LD50s. At 4 h or 12 233 hours post-exposure, designated animal groups received a single intravenous 234 administration of huPB10 by slow infusion at an individualized unit dose of 10 mg/kg. 235
Sham-treated animals received saline at the 4h time point. Treated animals were 236 observed for signs of adverse reactions to the MAb during administration and 237 throughout the anesthesia recovery period. Animals were bled just before and 24 h following aerosol challenge. Blood was also collected when the animals either 239 succumbed to intoxication or 21 d after challenge, when the experiment was terminated. 240
Animals determined to be in respiratory distress and those that survived for 21 d after 241 exposure to ricin were euthanized by an overdose of sodium pentobarbital, consistent 242 with the recommendation of the American Veterinary Medical Association's Panel on 243
Euthanasia, and submitted for necropsy. All methods were approved by the Tulane 244
University's IACUC. After gross necropsy, tissues were collected in neutral buffered 245 zinc-formalin solution (Z-Fix Concentrate, Anatach). Tissues were processed, 246 sectioned, and stained as previously described (3). Blood was also collected when the animals either succumbed to intoxication or 21 d 458 after challenge, when the experiment was terminated. 459 460 RT aerosolization, dosing, and calculation. Aerosolization, dosing and delivery of 461 ricin were performed as described (16) . Inductive plethysmography that measures 462 volume of air breathed by each individual animal per minute was performed just before 463 desired concentration for each animal based on plethysmography data obtained 2 d 465 before the exposure. Aerosols were generated directly into a head-only chamber using 466 a Collision three jet-nebulizer (BGI) with fully automated management control system 467 (Biaera Technologies, Hagerstown, MD) all within a Class III biological safety cabinet 468 housed within the TNPRC high-containment (BSL-3) laboratories. The nebulizer 469 operated at 18 lb/inch 2 equating to a flow of 7.5 L/min and produced 3.0E+04 particles 470 per cc with a mass median aerodynamic diameter of ∼1.4 µm. Each discrete aerosol 471 exposure lasted 10 minutes (per animal). Air samples were continuously obtained 472 during the exposure and the protein concentrations of these samples were determined 473 using a micro-BSA protein assay kit (Thermo Scientific). The aerosol concentrations 474 were determined and the inhaled dose of RT for each animal was calculated by 475 multiplying the empirically determined aerosol exposure concentration (µg/liter of air) in 476 the chamber by volume of air estimated to have been breathed by the animal (via 477 results of plethysmography just before exposure). The LD50 of ricin is 5.8 µg/kg body 478 weight and the target dose for this experiment was set at the equivalent of three LD50s 479 (»18 µg/kg). The mean inhaled dose of ricin across all animals was 4.4 ± 1.4 LD50s. 480 481 Statistics. Statistical analysis was carried out with GraphPad Prism 6 (GraphPad 482 Software, La Jolla California USA). The difference in outcomes between groups was 483 determined by Fisher's exact test (two-tailed) and the mean survival times after 484 exposure to ricin were compared by log-rank analysis of Kaplan-Meier survival curves. 485
Figure Legends
The statistical significance of the effects of ricin challenge and huPB10 intervention on 486 cytokine levels were analyzed with two-way repeated measures ANOVAs in both serum 487 and BAL, with the repeated measures being pre-and post-exposure status, and 488 treatment group as the independent measure. Resulting p-values were corrected with 489 the Benjamini, Krieger, and Yekutieli method to control false discovery rate. All 490 analyses were performed on log 2 transformed raw fluorescent intensity values to avoid 491 the need to censor values. PCA analysis was performed using singular value 492 decomposition with the R package FactoMineR (38). Heatmap construction using raw 493
fold change values was done using GraphPad Prism 6. Hierarchical clustering and Tissue Collection, Histological Analysis, and Special Stains. After gross necropsy, 497 tissues were collected in neutral buffered zinc-formalin solution (Z-Fix Concentrate, 498 Anatach). Tissues were processed, sectioned, and stained as previously described (3) 
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